PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|September 15, 2015
Raptor Drug Study Failure Wipes a Third Off Company Value
September 15, 2015.
Advertisement
Raptor Pharmaceutical (Novato, CA) will not continue with development of its liver drug RP103 after it failed to meet the main goal in a second mid-stage study, Reuters reports. The drug's failure in this study has cost more than a third of the company's market value, with shares falling as much as 43 percent to a more than two-year low of $6.83 on Monday. RP103 was being tested in children with nonalcoholic steatohepatitis (NASH). Raptor said however that it plans to continue further development of the drug in genetic disorders such as Huntington's and mitochondrial disease.
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Launches Rare Disease Framework Initiative
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5